Botulinum toxin (Botox) A for reducing the appearance of facial wrinkles: a literature review of clinical use and pharmacological aspect

Bagus Komang Satriyasa, Bagus Komang Satriyasa

Abstract

Background: Botulinum toxin (Botox) consists of 7 types of neurotoxins; however, only toxins A and B are used clinically. Botox A is used for several disorders in the field of medicine, particularly in dermatology, for cosmetic purposes. It is produced by the bacterium Clostridium botulinum and can be used as a treatment to reduce the appearance of wrinkles in the upper areas of the face, elevate the eyebrows and treat problems such as hyperhidrosis, lichen simplex, pompholyx (dyshidrotic eczema) and acne vulgaris. Objectives: This article provides a literature review regarding the general issue of Botox as a treatment for reducing facial wrinkle. Discussion: Botox works by blocking the release of acetylcholine, resulting in paralysis of the local muscles, which usually occurs 24 hrs to two weeks following Botox injection. This effect will last three to six months. The optimal dose of cosmetic Botox in dermatology is 20 units. Botox is relatively safe and does not result in any adverse side effects. However, in certain circumstances, the effect of Botox will gradually resolve, resulting in reduced muscle paralysis over time. Conclusion: Botox is good and safe medicine to reduce the appearance of facial wrinkles.

Keywords: Botox; botulinum toxin; drug; facial wrinkles.

Conflict of interest statement

The author reports no conflicts of interest in this work.

References

    1. Trindade de Almeida AR, Secco LC, Carruthers A. Handling botulinum toxins: an updated literature review. Dermatol Surg. 2011;37(11):1553–1565.
    1. Awan KH. The therapeutic usage of botulinum toxin (Botox) in non-cosmetic head and neck conditions – an evidence based review. Saudi Pharm J. 2017;25(1):18–24. doi:10.1016/j.jsps.2016.04.024
    1. Rohrer TE, Beer K. Background to botulinum toxin In: Carruthers A, Carruthers J, editors. Botulinum Toxin. USA: Elsevier Inc.; 2005:9–18.
    1. Carruthers A, Carruthers J. Botulinum toxin In: Bolognia JL, Jorizzo JL, Rapini RP, editors. Dermatology. 2nd ed. New York: Mosby Elsevier; 2008:2381–2390.
    1. Glogau RG. Botulinum toxin In: Wolf K, Goldsmith LA, Kartz SI, Gilchrest BA, Paller AS, Leffell DJ, editors. Fitzpatrick’s Dermatology in General Medicine. 7th ed. New York: McGraw Hill; 2008:2389–2395.
    1. Flynn TC. Advances in the use of botulinum neurotoxins in facial esthetics. J Cosmet Dermatol. 2012;11(1):42–50. doi:10.1111/j.1473-2165.2011.00593.x
    1. Klein AW. Complications with the use of botulinum toxin. Dermatol Clin. 2004;22(2):197–205.
    1. Markey AC. Botulinum A exotoxin in cosmetic dermatology. Clin Exp Dermatol. 2000;25(3):173–175.
    1. Rzany B, Zielke H. Overview of botulinum toxin In: de Maio M, Rzany B, editors. Botulinum Toxin in Aesthetic Medicine. New York: Springer-Verlag Berlin Heidelberg; 2007:1–10.
    1. Wollina U, Konrad H, Petersen S. Botulinum toxin in dermatology–beyond wrinkles and sweat. J Cosmet Dermatol. 2005;4(4):223–227. doi:10.1111/j.1473-2165.2005.00195.x
    1. Khawaja HA, Hernandez-Perez E. Botox in dermatology. Int J Dermatol. 2001;40(5):311–317.
    1. Lowe NJ. Minimally invasive treatments and procedures for aging skin In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook’s Textbook of Dermatology. 8th ed. London: Blackwell Publishing; 2010:80.1–80.14.
    1. Joel LC, Freeman SR. Botulinum toxins In: Draelos ZD, editor. Cosmetic Dermatology Products and Procedures. Oxford: Blackwell Publishing; 2010:342–351.
    1. Raspaldo H, Niforos F-R, Gassia V, et al.; Consensus Group. Lower-face and neck antiaging treatment and prevention using onabotulinumtoxin A: the 2010 multidisciplinary French consensus–part 2. J Cosmet Dermatol. 2011;10(2):131–149. doi:10.1111/j.1473-2165.2011.00560.x
    1. Michael AC, Kane MD. Botox injections for lower facial rejuvenation. Oral Maxillofac Surg Clin North Am. 2005;17(1):41–49. doi:10.1016/j.coms.2004.09.003
    1. Cohen JL, Dayan SH, Cox SE, Yalamanchili R, Tardie G. Onabotulinumtoxin A dose-ranging study for hyperdynamic perioral lines. Dermatol Surg. 2012;38(9):1497–1505. doi:10.1111/j.1524-4725.2012.02456.x
    1. Rzany B. Requirements and rules In: Philipp M, editor. Botulinum Toxin in Aesthetic Medicine. Berlin: Springer; 2007:21–24.
    1. Gart MS, Gutowski KA. Overview of botulinum toxins for aesthetic uses. Clin Plast Surg. 2016;43(3):459–471. doi:10.1016/j.cps.2016.03.003
    1. Cula GO, Bargo PR, Nkengne A, Kollias N. Assessing facial wrinkles: automatic detection and quantification. Skin Res Technol. 2013;19(1):e243–e251. doi:10.1111/j.1600-0846.2012.00635.x
    1. Simon C, Resto V, Quinn FB Jr, Quinn MS. Botulinum Toxin for Cosmetic Use. USA: UTMB Health ; 2010.
    1. Bauman L. Botulinum toxin In: Baumann L, Elsaie ML, Grunebaum L, editors. Cosmetic Dermatology. 2nd ed. New York: McGraw Hill; 2009:169–190.
    1. de Maio M, Rzany B. Injection technique In: Rzany B, editor. Botulinum Toxin in Aesthetic Medicine. New York: Springer-Verlag Berlin Heidelberg; 2007:25–26.
    1. Carruthers JA, Lowe NJ, Menter MA, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol. 2002;46(6):840–849.
    1. Krishtul A, Waldorf HA, Blitzer A. Complications of cosmetic botulinum toxin therapy In: Carruthers A, Carruthers J, editors. Botulinum toxin. USA: Elsevier Inc.; 2005:12132.
    1. Klein AW. Contraindications and complications with the use of botulinum toxin. Clin Dermatol. 2004;22(1):66–75. doi:10.1016/j.clindermatol.2003.12.026
    1. Carruthers A, Carruthers J. Upper face treatment In: Carruthers A, Carruthers J, editors. Botulinum Toxin. 1st ed. Philadelphia: Elsevier Saunders; 2005:31–43.
    1. Ascher B, Talarico S, Cassuto D, et al. International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood Unit)–part II: wrinkles on the middle and lower face, neck and chest. J Eur Acad Dermatol Venereol. 2010;24(11):1285–1295. doi:10.1111/j.1468-3083.2010.03728.x
    1. Maio M, Rzany B. Patient selection In: Acquilla R, Patel T, Gonzales M, editors. Botulinum Toxin in Aesthetic Medicine. New York: Springer; 2007:11–19.
    1. Carruthers A, Carruthers J, Said S. Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatol Surg. 2005;31(4):414–422.
    1. Hexsel C, Hexsel D, Porto MD, Schilling J, Siega C. Botulinum toxin type A for aging face and aesthetic uses. Dermatol Ther. 2011;24(1):54–61. doi:10.1111/j.1529-8019.2010.01378.x
    1. Cohen JL, Freeman SR. Botulinum toxins In: Draelos ZD, editor. Cosmetic Dermatology Products & Procedures. U: nited Kingdom: Wiley-Blackwell Publishing Ltd; 2010.
    1. Cox SE, Adigun CG. Complications of injectable fillers and neurotoxins. Dermatol Ther. 2011;24(6):524–536. doi:10.1111/j.1529-8019.2012.01455.x
    1. Klein AW. Complications, adverse reactions, and insights with the use of botulinum toxin. Dermatol Surg. 2003;29(5):549–556.
    1. Ogden S, Griffiths TW. A review of minimally invasive cosmetic procedures. Br J Dermatol. 2008;159(5):1036–1050. doi:10.1111/j.1365-2133.2008.08845.x
    1. Rzany B, Zielke H. Safety of botulinum toxin in aesthetic medicine In: de Maio M, Rzany B, editors. Botulinum Toxin in Aesthetic Medicine. New York: Springer-Verlag Berlin Heidelberg; 2007:119–125.
    1. Wang Y, Wang M, Xiao S, Pan P, Li P, Huo J. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol. 2013;14:147–153. doi:10.1007/s40257-013-0009-9
    1. Lim SH, Sun Y, Thiruvallur TM, Rosa V, Kang L. Enhanced skin permeation of anti-wrinkle peptides via molecular modification. Sci Rep. 2018;8:1596. doi:10.1038/s41598-017-18454-z
    1. Wang Y, Wang M, Xiao XS, Huo J, Zhang WD. The anti-wrinkle efficacy of Argireline. J Cosmet Laser Ther. 2013;15:237–241. doi:10.3109/14764172.2013.769273
    1. Raikou V, Varvaresou A, Panderi I, Papageorgiou E. The efficacy study of the combination of tripeptide-10-citrulline and acetyl hexapeptide-3. A prospective, randomized controlled study. J Clin Dermatol. 2017;15:271–278.
    1. Dayen SH. Complication from toxins and fillers in the dermatology clinic, recognition, prevention, and treatment. Facial Plast Surg Clin N Am. 2013;21:663–673. doi:10.1016/j.fsc.2013.07.008
    1. Alam M, Tung R. Injection technique in neurotoxins and fillers: indications, products, and outcomes. J Am Acad Dermatol. 2018;79(3):423–435. doi:10.1016/j.jaad.2018.01.037
    1. Hassouneh B, Newman JP. Laser, fillers, and neurotoxins avoiding complication in the cosmetic facial practice. Facial Plast Surg Clin N Am. 2013;21:585–598. doi:10.1016/j.fsc.2013.07.002
    1. Bellomo R, Harrington LK. Neurotoxins and dermal fillers: choosing the right product. Physician Assist Clin. 2016;1:333–345. doi:10.1016/j.cpha.2015.12.008
    1. Niamtu J. Complications in fillers and Botox. Oral Maxillofacial Surg Clin N Am. 2009;21:13–21. doi:10.1016/j.coms.2008.11.001
    1. Kim K, Jeon S, Kim J-K, Hwang JS. Effects of Kyunghee Facial Resistance Program (KFRP) on mechanical and elastic properties of skin. J Dermatol Treat. 2016;27(2):191–196. doi:10.3109/09546634.2015.1056078
    1. Ezure T, Hosoi J, Amano S, Tsuchiya T. Sagging of the check is related to skin elasticity, fat mass and mimetic muscle function. Skin Res Technol. 2009;15:229–305. doi:10.1111/j.1600-0846.2009.00364.x
    1. Castillo-Garzon MJ, Ruiz JR, Ortega FB, Gutierrez A. Anti-aging therapy through fitness enhancement. Clin Interv Aging. 2006;1:213–220.
    1. Clark HM, O’Brien K, Callej A, Corrie SN. Effects of directional exercise on lingual strength. J Speech Lang Hear Res. 2009;52:1034–1047. doi:10.1044/1092-4388(2009/08-0062)
    1. De Vos M-C, Den Brande HV, Boone B, Borsel JV. Facial exercises for facial rejuvenation: a control group study. Folia Phoniatr Logop. 2013;65:117–122. doi:10.1159/000354083

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi